GBS (Group B Streptococcus/-cocci) is a leading agent of severe, invasive bacterial infection in human newborns. Neonatal infection with this opportunistic pathogen can present as earlyonset or late-onset disease. In early-onset cases, bacteria are transferred from the mother to the infant in utero, following ascending infection of the placental membranes, or during passage through the birth canal, by aspiration of infected vaginal fluids. Early-onset neonatal infection manifests within the first few hours or days of life, often presenting as pneumonia and respiratory failure, which can quickly progress to bacteraemia and septic shock. By contrast, late-onset GBS disease can occur in infants up to several months old, and is distinguished by bloodstream infection with a high rate (40 -60%) of progression to meningitis (Ref. 1). Infants that survive GBS meningitis can suffer serious long-term neurological consequences, such as seizures, hearing loss and cognitive impairment. Serious GBS infections are increasingly recognised in adult populations, particularly in the elderly and individuals compromised by underlying medical conditions. More than 40% of all invasive GBS cases in the USA occur past infancy (Ref. 2).
The development of GBS disease reflects successful bacterial colonisation of the vaginal epithelium, penetration of placental or epithelial barriers, resistance to immune clearance allowing bloodstream survival and, in cases of meningitis, the ability to breach the endothelial blood -brain barrier (BBB). In overcoming these obstacles, GBS expresses a diverse array of surface-associated and secreted virulence factors that mediate specific host-cell interactions and interfere with innate immune clearance mechanisms. The present review explores knowledge of GBS virulence mechanisms at each key step of disease progression, with particular emphasis on the most recent molecular insights gained from studies of isogenic bacterial mutants using in vitro and in vivo models of GBS infection.
Adherence to host epithelial surfaces
The pathogenesis of GBS disease can first be traced toasymptomaticmucosalcolonisation,particularly of the maternal urogenital tract. Approximately 25% of healthy adults carry GBS, and the majority of babies born to a mother who harbours the bacteria will also become colonised (Ref. 3). GBS bind avidly to human vaginal epithelial cells under the low pH conditions characteristic of vaginal mucosa, through the low avidity interactions of cell-wall-associated lipoteichoic acid (LTA) and via higher-affinity interactions mediated by hydrophobic GBS surface proteins. Many of these GBS-host-cell interactions involve attachment of the bacterium to extracellular matrix (ECM) molecules such as fibronectin, fibrinogen and laminin, which in turn bind host-cell-surface proteins such as integrins (Fig. 1) .
ScpB, a GBS cell-surface protein previously characterised for its ability to cleave the complement-derived chemoattractant C5a, was identified in a phage-display screen for fibronectin binding (Ref. 4 
Invasion across host epithelial barriers
Following cellular adherence and colonisation, GBS can use secreted toxins or employ cellsurface virulence factors, known as invasins, to promote bacterial entry and survival within host cells (Fig. 1) . Some of these factors promote invasion by exploiting the ECM and/or host cellular signal transduction pathwaysmechanisms that are just beginning to be understood in the context of GBS infection. Ultimately, entry into epithelial cells provides GBS with an intracellular niche for survival, but can also result in breakdown of host tissue integrity and inflammatory activation, both of which may contribute to disease pathology. Importantly, infection of placental cells can promote ascending in utero infection, whereas invasion of pulmonary epithelium and endothelium promote systemic dissemination.
Migration Although cellular invasion may play a principal role in bloodstream penetration in late-onset GBS infection, extensive lung epithelial and endothelial destruction may be evident in severe early-onset cases. Cellular damage results largely from the actions of the GBS b-haemolysin/cytolysin, a pore-forming toxin that lyses lung epithelial and endothelial cells and compromises their barrier function (Refs 38, 39). Even at subcytolytic doses, GBS b-haemolysin/cytolysin promotes lung epithelial cell invasion and triggers release of interleukin-8 (IL-8), a principal neutrophil chemoattractant (Ref. 40) . GBS mutants lacking b-haemolysin/cytolysin expression are less able to penetrate pulmonary barriers and produce systemic infection than wild-type strains in a rabbit model of GBS pneumonia (Ref. 41 ). The cytolytic, proinvasive and proinflammatory effects of the GBS bhaemolysin/cytolysin are all neutralised by dipalmotyl phosphatidylcholine (DPPC), the major phospholipid constituent of lung surfactant (Ref. 38 ). This finding may help to explain the increased risk of premature, surfactant-deficient neonates to develop severe lung injury and invasive disease upon GBS infection.
The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been implicated in virulence of a number of bacterial pathogens including group A Streptococcus (GAS), through unanticipated dual functionalities that include binding and activation of host plasminogen (Ref. 42) . GAS acquisition of surface plasmin activity promotes host invasion and systemic spread (Ref. 43) . GBS GAPDH shares homology with GAS GAPDH and is expressed on the cell surface. GBS can bind lysine residues of host plasminogen via GAPDH, activate the bound proenzyme to plasmin, and thereby gain the ability to degrade host matrix proteins such as fibronectin (Ref. 44 Induction of phagocyte apoptosis, or programmed cell death, represents an alternative bacterial defence mechanism to avoid phagocytic clearance. Apoptosis is a carefully regulated signal cascade involving a group of cysteine proteases known as caspases and several pro-and anti-apoptotic regulators belonging to the Bcl-2 family. In contrast to some cell-death ligands, macrophage apoptosis triggered by GBS requires caspase-3 activation and utilises unique changes in regulation and localisation of Bcl-2 family members (Ref. 74 ). GBS-induced macrophage apoptosis can also progress independently of caspases. Here, calpains, which belong to a different class of cytosolic cysteine proteases, are recruited to cleave and activate Bcl-2 family members and relay the death signal; the dual pathways for phagocyte destruction increase the chances that host defences will be circumvented (Ref. 75 ). The complete role of GBS b-haemolysin/ cytolysin in the induction of apoptosis and/or necrotic macrophage cell death remains unclear. Production of this cytolysin was shown to enhance GBS survival in mouse and human blood and this pro-survival phenotype was linked to its ability to induce cytolysis and apoptosis of phagocytes (Ref. 68 ). Furthermore, growth of GBS in high glucose concentrations, which minimises b-haemolysin/cytolysin production, also reduces macrophage apoptosis (Ref. 76 ). However, it was also demonstrated that in vitro macrophage infection with either wild-type GBS or a GBS mutant lacking b-haemolysin/cytolysin resulted in similar levels of viability, indicating that GBS-induced macrophage apoptosis can also occur by a b-haemolysin/cytolysin-independent mechanism regulated, at least in part, by glucose (Ref. 76 1 hour) is manifested by increased pulmonary artery pressure and decreased arterial oxygenation, and is associated with a rise in serum levels of thromboxanes. Pulmonary hypertension and hypoxaemia persist through the late phase (2-4 hours), in which a progressive pattern of systemic hypotension, decreased cardiac output and metabolic acidosis develops together with haematological abnormalities, organ system dysfunction and an increase in inflammatory markers, such as thromboxanes, prostacyclins, tumor necrosis factor-alpha (TNF-a), IL-1 and IL-6.
IL-1, a known stimulator of cyclo-oxygenase and lipo-oxygenase pathways, appears to occupy a proximal position in the deleterious cytokine cascade of septic shock. Treatment with an IL-1 receptor antagonist improves cardiac output and mean arterial pressure and increases survival in piglets receiving a continuous infusion of GBS (Ref. 79) . Conversely, the cytokine IL-12, which is elevated 12-72 hours after challenge in animal models, has an important role in regulating the systemic response to GBS infection. Pretreatment with a monoclonal antibody against IL-12 results in greater mortality and intensity of bacteraemia, whereas therapeutic administration of IL-12 is associated with lower mortality and bloodstream replication of the organism (Ref. 80) .
Since the release of TNF-a, IL-l and IL-6 are stimulated by soluble GBS cell-wall antigens The role of complement in GBS-mediated inflammation remains controversial. In one study, whole blood derived from C3 or complement receptor 3 (CR3/CD11b/CD18) knockout mice infected with GBS revealed a tempered TNF-a response (Ref. 91) . NO was also shown to depend on CR3 expression in macrophages exposed to GBS (Ref. 92 ). However, others have shown that macrophages lacking CR3 demonstrate a normal cytokine response to GBS infection (Ref. 93 ).
The proinflammatory effects of the GBS bhaemolysin/cytolysin also contribute to sepsis pathophysiology. The toxin acts to stimulate iNOS and NO release in macrophages (Ref. 88) . In a mouse model of bacteraemia and arthritis, b-haemolysin/cytolysin expression is associated with higher mortality, increased bacterial loads, greater degrees of joint injury and intraarticular and systemic release of the proinflammatory cytokines IL-1 and IL-6 (Ref. 94) . Challenge of rabbits with isogenic GBS mutants showed that b-haemolysin/cytolysin production was associated with significantly higher degrees of hypotension, increased mortality and evidence of liver necrosis with hepatocyte apoptosis (Ref. 95) . Partially purified GBS b-haemolysin/cytolysin preparations produce significant hypotensive actions when infused in rats and rabbits, including death due to shock (Ref. 96 ). The b-haemolysin/cytolysin toxin contributes directly to cardiomyocyte dysfunction and apoptosis, which may augment its role in the pathophysiological abnormalities of GBS sepsis (Ref. 97) . 
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Research in progress and outstanding research questions
Each new year of GBS research heralds the discovery of novel virulence determinants or new functions for previously identified surface proteins or secreted factors. Advances can be attributed to the application of new methodologies, such as the use of reverse vaccinology to screen genomes for immunogenic surface antigens, which led to the identification multifunctional immunogenic adhesin BibA and unveiled the surface pili that had been overlooked for more than 50 years of GBS research (Refs 13, 59). Functional screening and careful reexamination of previously identified surface structures have also revealed secondary functions, such as a role for the GBS C5a peptidase ScpB in epithelial adherence or capsular sialic acid in engagement of host Siglec receptors. Furthermore, it is likely that GBS will remain a useful model organism for Gram-positive bacterial pathogenesis and for probing the developmental regulation of newborn immune function.
Rising incidences of invasive disease in adults and emerging patterns of antibiotic resistance (Ref. 123) indicate that further attention must be paid to elucidate GBS virulence factors and the mechanisms by which they interact with host cells and our immune system. Indeed, the emergence of GBS strains with decreased susceptibility to b-lactam antibiotics has now been reported in both the USA and Japan (Refs 124, 125). These GBS isolates harbour mutations in penicillin-binding protein 2x (PBP2x), which is similar to the first-step mutations on the pathway to full b-lactam resistance seen in pneumococcal isolates a few decades ago. Enhanced understanding of the molecular basis of GBS pathogenesis may pinpoint novel bacterial and host molecules that can represent novel therapeutic or immunoprophylactic targets against disease caused by this foremost of neonatal pathogens.
